Unlock value by optimising recombinant protein manufacture
We harness evolution and vast genetic diversity to create high-performance strains for scalable, low-cost recombinant protein production.
Strains that outperform. Products that scale.
We develop production strains that deliver performance where it counts—yield, cost, and IP protection. From proven biosimilars to novel peptides, our portfolio is designed to scale quickly and deliver commercial results.
Available to license now
Biosimilars
- Semaglutide, albumin, sargramostim
- Bioequivalence, lower cost, scalable production
Therapeutics
- High value low cost biologic therapeutics
- VHH, multi-valent vaccines, new indications of regulated biologics